HSCS
$2.65
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.
Intraday
Recent News
HeartSciences Inc. (HSCS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for HeartSciences Inc. (HSCS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
HeartSciences (HSCS) announced that the U.S. Food and Drug Administration has granted Breakthrough Device designationless than BDD, for its Aortic Stenosis ECG algorithm. The algorithm would offer a novel, AI-driven ECG solution capable of detecting moderate-to-severe aortic stenosis. Once cleared by the FDA, the algorithm will be accessible through HeartSciences’ MyoVista Insights cloud-based platform which would directly integrate with hospital electronic health record systems, requiring no ad
HeartSciences signs first MyoVista Insights platform customer
HeartSciences (HSCS) announced the signing of its first commercial customer for the MyoVista Insights platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month. Westcliffe Health Innovations provides cardiology services to the U.K. National Health Service in the Bradford and Leeds region. As the largest publicly funded healthcare system i